<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>One hundred and seventeen patients undergoing allogeneic bone marrow transplantation (BMT) for severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (n = 18) or <z:hpo ids='HP_0001909'>leukemia</z:hpo> (n = 99) who were alive on day +180, were analysed for the incidence and severity of <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (cGVHD), developing before or after discontinuation of <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi> (CSA) </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients received CSA for GVHD prophylaxis for 94 to greater than 988 days post-BMT </plain></SENT>
<SENT sid="2" pm="."><plain>cGVHD developed in 74 patients (63%) before CSA discontinuation (de novo n = 12, progression from <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD n = 42, following resolution of <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD n = 20) </plain></SENT>
<SENT sid="3" pm="."><plain>CSA was discontinued in 112 patients: electively (n = 80), because of toxicity (n = 8), or following relapse of <z:hpo ids='HP_0001909'>leukemia</z:hpo> (n = 24) </plain></SENT>
<SENT sid="4" pm="."><plain>In five patients CSA was never discontinued </plain></SENT>
<SENT sid="5" pm="."><plain>After discontinuation of CSA, progression or de novo cGVHD was seen in 25 patients, with a significant difference in patients treated for more or less than 150 days (8% vs 41%, p = 0.0007) </plain></SENT>
<SENT sid="6" pm="."><plain>In 15 patients CSA had to be re-instituted and in 14 it could be discontinued a second time </plain></SENT>
<SENT sid="7" pm="."><plain>Overall 111/117 (94%) patients have finally discontinued CSA </plain></SENT>
<SENT sid="8" pm="."><plain>In conclusion cGVHD will progress or appear de novo in 41% of patients receiving CSA for less and in 8% of those receiving CSA for more than 150 days respectively, indicating that the drug should be administered for at least 5 months post-BMT </plain></SENT>
<SENT sid="9" pm="."><plain>Most patients (94%) will eventually become CSA independent </plain></SENT>
</text></document>